Last reviewed · How we verify
NCT06711939: VCV
Vocorder Device Validation in Clinical Settings - Continuous Monitoring of Individuals (Vocorder Clinical Validation-VCV)
trial in Cancer of the Breast in 515 participants. Not yet recruiting.
31 August 2025
Quick facts
| Lead sponsor | Mitera Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 515 |
| Start date | 9 December 2024 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Greece |
Conditions studied
- Cancer of the Breast — all drugs for Cancer of the Breast →
- Cancer of Stomach — all drugs for Cancer of Stomach →
- Colon Cancer — all drugs for Colon Cancer →
- Lung Cancers — all drugs for Lung Cancers →
Sponsor
Mitera Hospital
Who can join
Adults 18 to 75, any sex, with Cancer of the Breast or Cancer of Stomach. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is performed under Vocorder project that is Co-Funded by the European Union. (Grant Agreement 101115442 VOCORDER HORIZON EIC-2022-PATHFINDERCHALLENGE-01). The projects has 9 work packages (one dedicated to the clinical study) and 12 partners (collaborators). MITERA Hospital serves as the project Coordinator as well as the leader of the clinical study. VOCORDER aims to create a paradigm shift in healthcare monitoring by developing a portable device for continuous assessment of health through breath analysis. Our mission is to make health monitoring seamless and non-intrusive, empowering individuals and healthcare professionals with real-time data and proactive health management. Our vision is to make continuous health monitoring a part of everyday life, helping in early disease detection and management. We are on a mission to create accessible, easy-to-use technology that integrates seamlessly into daily routines. Our objective is to create a tool designed for the discreet and continuous monitoring of human health. This involves the development and implementation of a system that can consistently assess, process, and analyze human breath. The key aim is to detect early indicators of diseases, thereby facilitating timely and proactive healthcare interventions. Strategic objectives 1. Provide a solution for easy-to-use breath analysis able to monitor the health of any individual at any setting. 2. Develop and demonstrate the beyond state-of-the-art technologies needed to implement the VOCORDER breath analysis apparatus. 3. Develop a health monitoring apparatus people can easily integrate into their everyday life. Scientific and technological Objectives 1. Demonstration of QCLs and ICLs monolithically integrated arrays. 2. Integrate QCLs/ICLs arrays with MPLC components for beam combing and providing high quality beam profile. 3. Implement a detector-less sensing scheme. 4. Enable AI-based breath analysis for the identification of health conditions. 5. Implement clinical studies of VOCORDER.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evaluating the VOCORDER device for early disease detection through breath analysis: study protocol for a two-phase clinical study.
Kontopidou F, Swift SJ, Kokkotis C, Moustakidis S, et al · · 2026 · PMID 42236089 · DOI 10.1136/bmjopen-2025-108562
Verify or expand the search:
- PubMed search for NCT06711939
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer of the Breast
Currently open trials in the same condition.
- NCT07067138 — A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS- · NA · recruiting
- NCT07072728 — Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder · Phase 2 · recruiting
- NCT06981208 — ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfacti · NA · recruiting
- NCT06749210 — DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY · Phase 2 · recruiting
- NCT05837455 — NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-ne · Phase 2 · recruiting
Other Mitera Hospital trials
Trials by the same sponsor.
- NCT07078760 — Lattice-tip Versus Irrigated-tip Catheter for Linear Ablation of the Cavotricuspid Isthmus. A Multicenter, Randomized St · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06711939 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mitera Hospital
- Last refreshed: 2 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06711939.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing